Researchers Probe GLP-1 Insurance Coverage Barriers
Researchers are investigating why insurance companies frequently deny coverage for GLP-1 weight-loss medications despite their proven health benefits. The study highlights the tension between the high societal value of these drugs and the massive budget impact their widespread use would create for insurers.
Why it matters
It addresses the critical economic and ethical challenges of making life-changing medical treatments accessible to the general public.
Despite growing evidence that GLP-1 medications improve health and are worth their cost, many insurance plans still limit coverage. University of Mississippi researchers are examining why, and where that leaves patients.
A recent report from the Institute for Clinical and Economic Review, an independent nonprofit that evaluates the value of medical treatments, found that GLP-1s such as Ozempic, Wegovy and Zepbound are cost-effective, meaning the medication's health benefits justify their price.
In a study published in the Journal of Managed Care and Specialty Pharmacy , Sujith Ramachandran, associate professor of pharmacy administration , said that "cost-effective" does not necessarily mean "cost-saving" for insurance companies.
"The ICER report shows that GLP-1s, at the cost that they are currently being sold, provide tremendous value to society," he said. "But the impact they create on the budget is still massive.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in